Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 in Allogeneic HSCT Recipients
NCT03565900Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2018
- Primary completion
- Nov 2021
- Modality
- Split/Subunit Vaccines
- Countries
- 10
01
Overview
A Phase 3 trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Sep 2018; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03565900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03565900.